The movement of drugs across biological membranes is mediated by two major classes of membrane transporters. Primary-active, ABC (ATP-binding cassette) multidrug transporters are dependent on ATPbinding/hydrolysis, whereas secondary-active multidrug transporters are coupled to the proton (or sodium)-motive force that exists across the plasma membrane. Recent work on LmrA, an ABC multidrug transporter in Lactococcus lactis, suggests that primary-and secondary-active multidrug transporters share functional and structural features. Some of these similarities and their implications for the mechanism of transport by ABC multidrug transporters will be discussed.
Similarities between ATP-dependent and ion-coupled multidrug transporters Introduction
The ever-increasing incidence of MDR (multidrug resistance) due to the overexpression of multidrug transporters is an important cause of failure of the drug-based treatment of patients with cancers or infections by pathogenic microorganisms [1, 2] . Even in non-overexpressing cells, drug efflux by multidrug transporters may interfere with the effective dosing of potentially efficacious drugs by altering the pharmacokinetic properties of these drugs [2, 3] .
Multidrug transporters exhibit a broad substrate specificity and are able to lower the intracellular drug concentration to subtoxic levels by mediating the active extrusion of drugs from the cell. They are integral membrane proteins, which can be broadly classified according to their bioenergetic requirements into primary-and secondary-active transporters. In primary-active transport, as is the case for ABC (ATP-binding cassette) multidrug transporters, the translocation of substrate is coupled directly to the hydrolysis of ATP [4] . In contrast, secondary-active transporters utilize the chemiosmotic energy derived from the electrochemical gradient of proton/sodium ions, which is present across the cytoplasmic membrane (also referred to as the proton/ sodium motive force). These systems mediate drug efflux in a drug/ion antiport reaction ( Figure 1 ) [5] . However, recent studies on the ABC multidrug transporter LmrA in Lactococcus lactis suggest that the boundaries between these two major classes of transporters might not be as distinct as was originally thought [6] . In this review, these studies will be discussed in the context of functional and structural similarities that can be observed between primary-and secondaryKey words: ATP-binding cassette transporter (ABC transporter), carboxylate, LmrA, multidrug resistance, secondary-active transporter, transmembrane segment (TMS). Abbreviations used: ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; MD, membrane domain; MDR, multidrug resistance; MFS, major facilitator superfamily; MRP, multidrug resistance protein; NBD, nucleotide-binding domain; RND, resistance-nodulation-cell division; SMR, small multidrug resistance; TMS, transmembrane segment. 1 To whom correspondence should be addressed (email hwv20@cam.ac.uk).
active multidrug transporters in prokaryotic and eukaryotic cells.
ABC transporter with a secondary-active multidrug translocator domain
Bacterial LmrA is a homologue of the human MDR P-glycoprotein MDR1 (also termed ABCB1) and can functionally substitute for P-glycoprotein in human lung fibroblast cells [7] . LmrA consists of an N-terminal MD (membrane domain), containing six TMS (transmembrane segments), followed by the NBD (nucleotide-binding domain). The protein homodimerizes to form the minimal functional unit containing two MDs and two NBDs [8] . In P-glycoprotein, these four domains are fused into a single polypeptide. The MDs contain the substrate translocation pathways, whereas the NBDs couple the transport reaction at the MD to ATPbinding/hydrolysis [2, 4] . When a truncated LmrA protein was generated containing the MD in the absence of the NBD, this protein (termed LmrA-MD) retained the substrate specificity of the full-length protein, but mediated drug influx instead of efflux [6] . Detailed biochemical analysis of purified LmrA-MD, functionally reconstituted into proteoliposomes, revealed that the protein transports drugs in a proton motive force-dependent fashion by catalysing a drug/H + symport reaction analogous to that of secondary-active solute uptake systems. Similar to LmrA-MD, full-length LmrA can mediate drug/H + co-transport during ATP-dependent efflux [6] . In another study, it was observed that in the presence of an inwardly directed drug concentration gradient in ATPdepleted cells, LmrA can mediate the reverse transport (or uptake) of drug [9] . This uptake reaction was competitively inhibited by LmrA substrates and was also affected by mutations in the NBD or MD, which inactivate these domains or reduce their activity. As LmrA can mediate drug influx and efflux, these observations on LmrA and LmrA-MD pointed to the reversibility of drug transport. This conclusion is striking, as reversibility of substrate transport is usually linked to secondary-active transporters; ABC transporters are often thought to be unidirectional [9] . Interestingly, a significant sequence similarity has recently been observed between LmrA and MexB, a secondary-active multidrug transporter belonging to the RND (resistance-nodulation-cell division) family. The shared sequence corresponds to a hairpin region of two membrane-spanning helices and the connecting loop between these helices [10] . Our findings generate the interesting question whether substrate translocation mechanisms are conserved between primary-and secondary-active multidrug transporters and also whether the functional similarity is supported by further structural similarities between these two classes of proteins.
Conservation of global structure of MDs
As the MDs of transporters form the pathways through which substrates are translocated across the phospholipid bilayer and hence, contain substrate-binding sites, it is interesting to compare MDs of primary-and secondary-active transporters at the structural level. Even though, in general there is little overall sequence identity between MD regions of members of these two classes of transporters, or even between members within each class, interesting similarities exist between the secondary and tertiary structures of MDs. Recent crystal structures for members of the MFS (major facilitator superfamily) and for ABC transporters reveal that MDs are mostly α-helical [11] [12] [13] [14] [15] [16] and that these helices often span the membrane in a two-times-six helices motif. Although some members of the MFS consist of 14 TMS, the two additional segments can easily be removed without complete loss of transport activity [17] . Likewise, certain mammalian MRPs (multidrug resistance proteins) contain an additional N-terminal MD containing five TMS, in addition to the two MDs found in P-glycoprotein and dimeric LmrA. This extra domain can be removed without compromising drug transport activity [18] . Even transporters of the SMR (small multidrug resistance) family, containing four TMS, seem to abide to the two-times-six helices rule. A recent X-ray crystal structure of the Escherichia coli SMR member EmrE revealed a tetramer consisting of two heterodimers with inverted orientation with respect to each other. Each heterodimer forms a six-helical bundle, consisting of helices 1, 2 and 3 of each monomer, while helix 4 does not form part of this six-helix arrangement [19] . However, some caution is needed here, as a different tertiary structure was obtained for dimeric EmrE by electron crystallography [20] . The overall similarity between structures of MDs of ABC transporters and secondary-active transporters may suggest that the mechanical movements of helices induced by substrate binding and transport might be similar, e.g. based on rigidbody movement of the two six-helix domains against one another. This movement would then allow alternating access of substrate-binding sites to the inner and outer membrane surface. Indeed, this notion is consistent with structural data for both secondary-active transporters (LacY, GlpT and OxltT) and ABC transporters (MsbA and BtuCD) [11] [12] [13] [14] [15] [16] 21] .
Similarities in drug-binding sites
Given that the substrate specificities of primary-and secondary-active multidrug transporters overlap, it follows that there may be similarities in the drug-binding pockets of these transporters. Much insight into multidrug binding has been gained from X-ray crystallography on soluble multidrug-binding transcriptional regulators such as BmrR in Bacillus subtilis and QacR in Staphylococcus aureus [22] [23] [24] . BmrR activates the expression of the secondary-multidrug transporter Bmr in response to the binding of amphiphilic compounds [24] . Cationic tetraphenylphosphonium is able to penetrate into the hydrophobic core of BmrR, where it forms hydrogen bonds and stacking interactions with hydrophobic and aromatic residues, and makes an ion-pair interaction with a buried glutamate residue (Glu 134 ) [23, 24] . Similar to BmrR, drug binding to QacR creates an expansive multisite drug-binding pocket in which four buried glutamate residues, Glu 57 , Glu 58 , Glu 90 and Glu 120 , are available to neutralize positively charged moieties in stereochemically dissimilar drugs [22] .
Since the amphiphilic compounds that bind to BmrR and QacR are transported by Bmr and QacA/B and many other multidrug transporters, similar drug-protein interactions may occur in all these proteins [25] [26] [27] . Indeed, the importance of carboxylates in a hydrophobic environment, in the translocation of cationic drugs by secondary-active multidrug transporters is well documented. A carboxylate in the first TMS is highly conserved in multidrug transporters of the MFS and the SMR families [28] . The MFS transporter, MdfA from E. coli, for example, contains a single membrane embedded glutamate (Glu 26 ) in the middle of TMS 1. Mutation of this glutamate residue has a profound effect on the substrate recognition profile of MdfA. The carboxylate at position 26 is essential for the transport of cationic drugs, while the transport of neutral chloramphenicol is unaffected. Therefore Glu 26 is likely to be part of the substrate-binding site [29] .
QacA and QacB are 14 TMS secondary-active MFS multidrug efflux proteins from the pathogen S. aureus [30] . These transporters share substantial sequence identity, but differ in that QacA confers resistance on uni-as well as bi-valent cations, while QacB only confers resistance on univalent cations. This difference is due to the presence of an aspartate (Asp 323 ) in TMS 10 of QacA. QacB mutants containing an acidic residue at the equivalent position displayed resistance to bivalent cations similar to QacA [30] . Carboxylates important for substrate specificity have also been identified in the secondary-active multidrug transporter LmrP from L. lactis [31] .
To date, much less is known about the role of carboxylates in drug-protein interactions in ABC transporters. The human BCRP (breast cancer resistance protein; also referred to as ABCG2 or mitoxanthrone resistance protein) contains only one membrane-embedded acidic residue, Glu 446 in TMS 2. Even a conserved mutation of this residue to an aspartate resulted in a marked decrease in mitoxanthrone and SN-38 efflux in BCRP-expressing cells [32] . A single membrane-embedded carboxylate in TMS 2 is also a feature of the 'topological homologues' of BCRP such as the ABC multidrug transporter Pdr5p in Saccharomyces cerevisiae and Cdr1p in Candida albicans. Although as yet untested, these acidic residues are probably important for substrate recognition too. Carboxylates with a possible role in drug binding have also been identified in the second MD (TMS 6-11) of mammalian MRP1 (ABCC1) [33] . Interestingly, certain ABC transporters, including LmrA and P-glycoprotein, do not contain Glu/Asp residues in the TMS. Interactions between these proteins and cationic drugs will be based on similar principles as observed in mammalian ion channels and receptor proteins, where aromatic residues can stabilize the binding of ligands with cationic and aromatic moieties through cation-π and π -π (stacking) interactions respectively [34] [35] [36] .
Many of the biochemical observations listed above were confirmed in crystallographic studies on AcrB, an MFS member in E. coli [37, 38] . The structure shows the presence of an expanded drug-binding pocket, as observed for BmrR and QacR, lined with aromatic amino acids and containing buried carboxylates. Drugs bind to this surface through stacking of their aromatic rings to aromatic residues, while the positively charged moieties form electrostatic interactions with the dissociated carboxylates [37, 38] .
Role of carboxylates in proton transport
Carboxylates are also known to play an essential role in proton translocation by many secondary-active transporters, including drug transporters such as EmrE and the tetracycline transporter TetA(B). EmrE contains only one membrane-embedded carboxylate (Glu 14 ). An array of biochemical data implicates Glu 14 in the binding of cationic drugs as well as protons [39] [40] [41] . A mechanism was proposed, where drugs and protons bind to Glu 14 in a mutually exclusive fashion: (i) a drug interacts with Glu 14 in a substrate-binding site at the inside surface of the membrane, (ii) the liganded substrate-binding site reorients to the outside surface of the membrane, and (iii) reprotonation of Glu 14 promotes dissociation of the substrate [42] .
Recently, evidence was obtained for a role of carboxylates in proton transport by ABC transporters. In a homology model of LmrA based on the Vibrio cholera MsbA structure, a glutamate residue (Glu 314 ) was identified that is present in a hydrophobic environment at the membrane-cytoplasm interface of TMS 6 [43] . Interestingly, Glu 314 is essential for proton-coupled drug transport by LmrA [6, 43] . Glu 14 in EmrE and Glu 314 in LmrA both displayed an elevated pKa value, and a conserved Glu to Asp mutation changed the pH dependence of drug transport for both proteins. These observations suggest that, similar to Glu 14 in EmrE, Glu 314 in LmrA may have a mechanistic role in drug transport, e.g. by coupling conformational changes in the NBD (induced by ATP-binding/hydrolysis) to conformational changes in the MD associated with transport. In this context, it is noteworthy that replacement of Glu 1204 at the membranecytoplasm interface of TM17 of MRP1 uncoupled its catalytic and transport activities [44] . Alternatively, proton transport by LmrA might result from drug/proton-protein interactions reminiscent of those described for EmrE. The ability of LmrA to mediate proton extrusion may also relate to an unidentified role of this transporter in the physiology of L. lactis.
Conclusion
It is clear that ABC-type and secondary-active multidrug transporters share many structural and functional features. These features might reflect a similarity in conformational changes during transport, which could be based on common biochemical mechanisms for drug binding and translocation.
